Board of Overseers

The Board of Overseers is an advisory body committed to providing counsel and support to the ADDF Board of Governors and staff. Overseers lend their expertise to advance the ADDF's mission to accelerate the discovery of drugs to prevent, treat and cure Alzheimer’s disease. Overseers are appointed by and serve at the pleasure of the Board of Governors.

  • Carol Seabrook Boulanger
    Partner, Pillsbury, Winthrop, Shaw, and Pittman, LLP

  • Charles Cangro
    Principal, Personal Financial Services, Ernst & Young

  • Mitchell D. Eichen, J.D., LL.M.
    Founder and Chief Executive Officer, Acertus Capital Management
    Founder and Chief Executive Officer, The MDE Group

  • Allan M. Green, MD, PhD, JD
    Allan M. Green Esq., LLC

  • Christopher Johnson
    President and Managing Officer, Rackson Corporation

  • Elise Gelman Lefkowitz
    Philanthropist

  • Philip Lovett
    Founding Partner, Millennium Partners

  • Emilio Matt
    Business Development Director, Microsoft Corporation

  • Pamela J. Newman, Ph.D.
    President and Chief Executive Officer, The Newman Team, Aon Corporation

  • Phebe Farrow Port
    Senior Vice President, Global Management Strategies and Chief of Staff, Executive Management Initiatives, The Estée Lauder Companies Inc.

  • Sharon T. Sager, CIMA
    Co-chair, ADDF Board of Overseers
    Managing Director and Private Wealth Advisor, UBS Private Wealth Management

  • Randal Sandler
    Vice Chairman, ADDF Board of Governors
    Director of Client Services and Marketing, Bridgewater Associates

  • John H. Scully, CIMA
    Senior Vice President, Global Private Client Group, Nuveen Investments

  • Mary Rose Taylor
    Strategic Advisor, Emory ADRC

  • Stephen Toma
    Managing Director, VJMS, LLC

  • Wendy L. Wilshin
    Founder and Principal, WLW Designs

  • Alison Zaino
    Philanthropist

  • Linda S. Zambelli
    Managing Director, U.S. Trust, Bank of America Private Wealth Management

Go to top